Adalimumab is a TNF-α inhibitor used in clinical practice in the treatment of many diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), and juvenile idiopathic arthritis [21]. This evidence concerns the gene TNF and ankylosing spondylitis.